OMEGA-3 FATTY ACIDS, DIABETES AND CARDIOVASCULAR RISK

描述：我们希望召开一个国际研讨会，题为“欧米茄-3” 脂肪酸、糖尿病和心血管风险。“研讨会将于 2000年11月30日至12月2日，马里兰州贝塞斯达。长链海洋欧米茄-3 脂肪酸[主要是二十碳五烯酸（EPA）和二十二碳六烯酸 [DHA]最近被证明可以将总死亡率降低20%， 既存心血管（CV）疾病患者。本次研讨会将（1） 讨论和评估目前关于潜在的科学证据， ω-3脂肪酸在降低心血管疾病中的作用 (CVD)糖尿病患者中的风险，2）评估进行 确定性临床试验，以确定ω-3脂肪酸是否降低CVD风险 在糖尿病患者中，和3）如果认为是及时开始这样的试验， 概述适当的研究设计;如果没有，确定额外的研究是什么 needed.所涉及的专题将包括评估 糖尿病对心血管疾病风险的影响; 糖尿病患者中omega-3脂肪酸作用的机制 (e.g.,对基因表达、葡萄糖转运蛋白和过氧化物酶体的影响 增殖物激活受体）;讨论omega-3脂肪酸的作用 几种CV风险因素（例如，脂质和脂蛋白，血栓形成， 内皮功能，血压，心功能，易感性 心律失常、心率变异性、炎症和粘附分子 表达）;以及评估omega-3脂肪酸在糖尿病中的安全性。我们 还将审查来自糖尿病亚群的未发表的CV结局数据 在最近完成的一项使用omega-3脂肪酸的随机临床试验中，的 研讨会将以广泛的讨论结束，这将导致 合理的临床实施建议（如有）， 未来的研究。特别是，我们将讨论及时性问题， 建立一个大规模的，随机的，临床试验来评估 omega-3脂肪酸在糖尿病中的预防潜力。这将是第一 特别关注omega-3脂肪酸、糖尿病和CV的会议 我们计划在糖尿病杂志上发表它的论文。的 研讨会的结论和建议将向公众公布。 和私人融资机构。

DESCRIPTION: We wish to convene an international workshop entitled, "Omega-3 Fatty Acids, Diabetes and Cardiovascular Risk." The workshop would be held in Bethesda, MD on November 30-December 2, 2000. The long-chain, marine omega-3 fatty acids [primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have recently been shown to reduce total mortality by 20 percent in patients with preexisting cardiovascular (CV) disease. This workshop will 1) discuss and evaluate the current scientific evidence regarding the potential role of omega-3 fatty acids (omega-3 FAs) in reducing cardiovascular disease (CVD) risk in diabetic patients, 2) assess the timeliness of undertaking a definitive clinical trial to determine whether omega-3 FAs reduce risk for CVD in diabetic patients, and 3) if it is deemed timely to initiate such a trial, outline a proper study design; if not, determine what additional research is needed. The topics to be covered will include an evaluation of the effects of diabetes on CV disease risk; a review of the biochemical and physiological mechanisms responsible for the effects of omega-3 FAs in diabetic patients (e.g., effects on gene expression, glucose transporters, and peroxisome proliferator-activated receptors); a discussion of the effects of omega-3 FAs on several CV risk factors (e.g., lipid and lipoproteins, thrombosis, endothelial function, blood pressure, cardiac function, susceptibility to arrhythmias, heart rate variability, inflammation and adhesion molecule expression); and an evaluation of the safety of omega-3 FAs in diabetes. We will also review unpublished CV outcomes data from the diabetic sub-population in a recently completed randomized clinical trial using omega-3 FAs. The workshop will end with extensive discussions, which will result in well-reasoned recommendations for both clinical implementation (if any) and future research. In particular, we will address the question of the timeliness of instituting a large-scale, randomized, clinical trial to evaluate the preventive potential of omega-3 FAs in diabetes. This will be the first conference to specifically focus on omega-3 fatty acids, diabetes, and CV disease, and we plan on publishing its proceedings in a diabetes journal. The conclusions and recommendations of the workshop will be communicated to public and private funding agencies.